Beximco Pharma exports second drug to the US market

Beximco Pharmaceuticals Limited Beximco is only pharmaceutical company to export pharmaceutical products to the United States (US) is now going to export Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US market. This comes, after the successful launch of Carvedilol to the US in August 2016. According to QuintlesIMS data, the market size for Satalol Hydrochloride (including all strengths) in the US is $23 million. The first consignment was delivered on 29 October 2017 and the product will be distributed through the Company’s existing partner in the US. “We are delighted to strengthen our presence in the US with the launch of our second product in this market. With the export of our first product to the US in August 2016, we began a new era for the pharmaceutical industry in Bangladesh that we will continue to build with the launch of Sotalol,” Beximco Pharma Managing Director Nazmul Hassan said. “Beximco Pharma remains the only Bangladeshi company to export pharmaceutical products to the US, which is a validation of our expertise in offering specialised generic products in a global setting,” said Nazmul. “With this, we will focus on increasing our presence in the world’s largest pharmaceutical market in the coming years,” he added.